#1 Clinical Trials Search in Europe

Mps-213

This article examines ongoing clinical trials investigating the use of MPS-213, a component of the cancer vaccine Tedopi (OSE2101), in treating various types of cancer. These trials aim to evaluate the safety and efficacy of MPS-213 as part of combination therapies or maintenance treatments for patients with advanced cancers, including non-small cell lung cancer, ovarian cancer, and pancreatic cancer.

Table of Contents

What is MPS-213?

MPS-213 is one of the active substances in TEDOPI, a cancer vaccine developed by OSE Immunotherapeutics[1]. TEDOPI is a combination of 10 synthetically manufactured peptides, including MPS-213, designed to stimulate the immune system to fight cancer cells[2]. This type of treatment is known as immunotherapy, which harnesses the body’s own immune system to target and destroy cancer cells.

How Does MPS-213 Work?

As part of the TEDOPI vaccine, MPS-213 works by activating the body’s T cells, which are a crucial component of the immune system. The vaccine is designed to target specific proteins found on cancer cells, helping the immune system recognize and attack these cells more effectively[1]. This targeted approach aims to provide a more personalized treatment for cancer patients.

What Conditions Does MPS-213 Treat?

MPS-213, as a component of TEDOPI, is being studied for the treatment of several types of cancer, including:

  • Non-Small Cell Lung Cancer (NSCLC): TEDOPI is being investigated for patients with advanced or metastatic NSCLC, particularly those who have developed resistance to previous immunotherapy treatments[1].
  • Ovarian Cancer: Clinical trials are exploring the use of TEDOPI in patients with recurrent ovarian cancer[3].
  • Pancreatic Cancer: Research is ongoing to evaluate TEDOPI’s effectiveness in treating locally advanced or metastatic pancreatic ductal adenocarcinoma[4].

Clinical Trials Involving MPS-213

Several clinical trials are currently underway to assess the safety and efficacy of TEDOPI, which contains MPS-213:

  • ARTEMIA Study: A phase 3 trial comparing TEDOPI to docetaxel in patients with metastatic NSCLC who have developed resistance to immune checkpoint inhibitors[1].
  • TEDOVA Study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer[3].
  • TEDOPAM Study: A phase 2 trial investigating TEDOPI in combination with FOLFIRI chemotherapy as a maintenance treatment for patients with advanced pancreatic cancer[4].

How is MPS-213 Administered?

TEDOPI, which contains MPS-213, is administered as an emulsion for injection. It is typically given through subcutaneous injection, which means it is injected just under the skin[2]. The exact dosing schedule may vary depending on the specific clinical trial or treatment protocol.

Potential Side Effects

As with any medical treatment, TEDOPI may cause side effects. While specific information about MPS-213 side effects is not provided, common side effects of cancer vaccines and immunotherapies may include:

  • Injection site reactions (redness, swelling, or pain)
  • Flu-like symptoms (fever, chills, fatigue)
  • Nausea or vomiting
  • Muscle or joint pain

It’s important to note that the safety profile of TEDOPI is still being evaluated in ongoing clinical trials[3][4].

Patient Eligibility for MPS-213 Treatment

Eligibility for treatment with TEDOPI, which contains MPS-213, may vary depending on the specific clinical trial or treatment protocol. However, some general criteria include:

  • HLA-A2 Positive Status: Patients must have a specific genetic marker called HLA-A2 to be eligible for TEDOPI treatment[1].
  • Cancer Type and Stage: Eligibility is typically limited to patients with specific types and stages of cancer, such as advanced NSCLC, recurrent ovarian cancer, or metastatic pancreatic cancer[1][3][4].
  • Previous Treatments: Some trials focus on patients who have developed resistance to previous immunotherapy treatments or have received specific prior therapies[1].
  • Overall Health Status: Patients must generally be in good overall health, with adequate organ function and a good performance status[3][4].

It’s important for patients to discuss their eligibility for TEDOPI treatment with their healthcare provider, as they can provide the most up-to-date and personalized information based on individual medical history and current health status.

Trial Name Cancer Type Phase Main Objective Key Eligibility Criteria
ARTEMIA Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 3 To confirm the superiority of OSE2101 versus docetaxel on Overall Survival (OS) HLA-A2 positive, secondary resistance to Immune Checkpoint Inhibitor
OSE-279 Combination Study Advanced solid tumors, lymphomas, metastatic NSCLC Phase 1/2 Determine Maximum Tolerated Dose and assess antitumor activity of OSE-279 alone and in combination with OSE2101 HLA-A2 positive for NSCLC cohort, measurable disease
TEDOVA Platinum-sensitive recurrent ovarian cancer Phase 2 Evaluate Progression Free Survival (PFS) of OSE2101 alone or with pembrolizumab vs best supportive care HLA-A2 positive, controlled disease after platinum-based chemotherapy
TEDOPAM Locally advanced or metastatic pancreatic ductal adenocarcinoma Phase 2 Assess Overall Survival of OSE2101 plus FOLFIRI vs FOLFIRI alone as maintenance therapy HLA-A2 positive, stable disease after FOLFIRINOX induction chemotherapy

FAQ

  • What is MPS-213? MPS-213 is one of the active substances in Tedopi (OSE2101), which is a cancer vaccine being studied in clinical trials. It is part of a combination of synthetically manufactured peptides designed to stimulate the immune system to fight cancer cells.
  • What types of cancer are being studied with MPS-213? The clinical trials are investigating MPS-213 (as part of Tedopi) in various cancer types, including non-small cell lung cancer (NSCLC), ovarian cancer, and pancreatic ductal adenocarcinoma.
  • How is MPS-213 administered to patients? MPS-213, as a component of Tedopi, is typically administered as a subcutaneous injection or emulsion for injection.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing overall survival, progression-free survival, safety profiles, and the efficacy of MPS-213 (as part of Tedopi) in combination with other treatments or as maintenance therapy for various advanced cancers.
  • Who is eligible to participate in these clinical trials? Eligibility varies by trial but generally includes adult patients with specific cancer types, adequate organ function, and certain HLA-A2 phenotypes. Patients must meet specific criteria regarding previous treatments and current health status.

Ongoing Clinical Trials on Mps-213

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • MPS-213: One of the active substances in the cancer vaccine Tedopi (OSE2101), which is being studied in clinical trials for various types of cancer.
  • Tedopi (OSE2101): A cancer vaccine containing multiple synthetically manufactured peptides, including MPS-213, designed to stimulate the immune system against cancer cells.
  • HLA-A2 phenotype: A specific type of human leukocyte antigen (HLA) present on cells. Some clinical trials require patients to have this phenotype to participate.
  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer being studied in some of the clinical trials involving MPS-213.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Maintenance therapy: Treatment given to help keep cancer from coming back after it has responded to initial therapy.
  • Immune checkpoint inhibitor: A type of drug that blocks certain proteins made by immune system cells and some cancer cells, potentially allowing immune cells to kill cancer cells more effectively.
  • FOLFIRINOX: A combination chemotherapy regimen used in the treatment of pancreatic cancer, consisting of folinic acid, fluorouracil, irinotecan, and oxaliplatin.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/